Acadia Pharmaceuticals
ACAD
142 hedge funds and large institutions have $2.18B invested in Acadia Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 51 increasing their positions, 46 reducing their positions, and 7 closing their positions.
1,326% more call options, than puts
Call options by funds: $373M | Put options by funds: $26.2M
300% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 7
46% more capital invested
Capital invested by funds: $1.5B → $2.18B (+$683M)
15% more funds holding
Funds holding: 123 → 142 (+19)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
11% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 46
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$43.1M |
| 2 |
Alkeon Capital Management
New York
|
+$35.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$20M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$11.9M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$94M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$30.9M |
| 3 |
O
OrbiMed
New York
|
-$20.5M |
| 4 |
DM
Deerfield Management
New York
|
-$19.4M |
| 5 |
VAM
Visium Asset Management
New York
|
-$16.3M |
ACAD Hedge Fund Activity: Q3 2013 in Review
142 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q3 2013, worth a combined $2.18B — up 46% from $1.5B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ACAD positions and 7 closed out — a net gain of 21 holders — while 51 added to existing stakes and 46 trimmed.
The largest buyer was Westfield Capital Management, opening a new position worth an estimated $43.1M. The largest seller was RA Capital Management, cutting an estimated $94M.
- 142 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q3 2013, up from 123 in Q2 2013.
- Funds reported $2.18B of Acadia Pharmaceuticals stock for Q3 2013, up 46% quarter-over-quarter.
- 28 funds opened new Acadia Pharmaceuticals positions in Q3 2013 and 7 closed out, a net change of +21 holders.
- The largest Acadia Pharmaceuticals buyer in Q3 2013 was Westfield Capital Management, an estimated $43.1M added.
- The largest Acadia Pharmaceuticals seller in Q3 2013 was RA Capital Management, an estimated $94M sold.
Based on aggregated 13F filings for Q3 2013.